Rebif (Multiple Sclerosis)：市場予測と分析（～2022）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 7
2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 9
3 Disease Overview 11
3.1 Etiology and Pathophysiology 11
3.1.1 Etiology 11
3.1.2 Pathophysiology 12
3.1.3 Classification of Multiple Sclerosis 13
3.2 Symptoms 15
3.2.1 Prognosis 16
3.2.2 Quality of Life 17
4 Disease Management 18
4.1 Diagnosis 18
4.2 Treatment Overview 21
4.2.1 Management of Acute Relapse 22
4.2.2 Treatment with Disease-Modifying Therapies 22
4.2.3 Symptomatic Therapies 25
5 Competitive Assessment 26
5.1 Overview 26
5.2 Strategic Competitor Assessment 27
6 Rebif (interferon beta-1a) 29
6.1 Overview 29
6.2 Efficacy 30
6.3 Safety 31
6.4 SWOT Analysis 31
6.5 Forecast 33
7 Appendix 34
7.1 Bibliography 34
7.2 Abbreviations 38
7.3 Methodology 40
7.4 Forecasting Methodology 40
7.4.1 Diagnosed MS patients 40
7.4.2 Percent Drug-Treated Patients 41
7.4.3 General Pricing Assumptions 41
7.4.4 Individual Drug Assumptions 42
7.4.5 Generic Erosion 42
7.5 Physicians and Specialists Included in This Report 43
7.6 Primary Research – Prescriber Survey 44
7.7 About the Authors 45
7.7.1 Analysts 45
7.7.2 Global Head of Healthcare 46
7.8 About GlobalData 47
7.9 Contact Us 47
7.10 Disclaimer 47